Article

Single dose immunization with a COVID-19 DNA vaccine encoding a chimeric homodimeric protein targeting receptor binding domain (RBD) to antigen-presenting cells induces rapid, strong and long-lasting neutralizing IgG, Th1 dominated CD4 + T cells and strong CD8 + T cell responses in mice

2020-12-09

Abstract excerpt

The pandemic caused by the SARS-CoV-2 virus in 2020 has led to a global public health emergency, and non-pharmaceutical interventions required to limit the viral spread are severely affecting health and economies across the world. A vaccine providing rapid and persistent protection across populations is urgently needed to prevent disease and transmission. We here describe the development of novel COVID-19 DNA plas...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bd6f91b2-9f34-5edd-aa78-0b199fca887b
DOI: 10.1101/2020.12.08.416875

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Single dose immunization with a COVID-19 DNA vaccine encoding a chimeric homodimeric protein targeting receptor binding domain (RBD) to antigen-presenting cells induces rapid, strong and long-lasting neutralizing IgG, Th1 dominated CD4 + T cells and strong CD8 + T cell responses in miceDOI 10.1101/2020.12.08.416875Read

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2Semantic proximity Read

Translational Virology - COVID-19, The Perfect ExampleSemantic proximity Read

Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variantsSemantic proximity Read

An Overview of Vaccine Development for COVID-19Semantic proximity Read

Safety and immunogenicity of a recombinant DNA COVID-19 vaccine containing the coding regions of the spike and nucleocapsid proteins: Preliminary results from an open-label, phase 1 trial in healthy adults aged 19–55 yearsSemantic proximity Read

Rapid development of a synthetic DNA vaccine for COVID-19Semantic proximity Read

Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious DiseasesSemantic proximity Read

COVID-19 Vaccines: Where Do We Stand at the End of 2023?Semantic proximity Read

COVID- e Vax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain, elicits protective immune responses in animal models of COVID-19Semantic proximity Read

Nanocell COVID-19 vaccine elicits iNKT-licensed dendritic cells to produce high affinity antibodies neutralizing Variants of ConcernSemantic proximity Read

COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal modelsSemantic proximity Read